Tallahassee, FL 10/27/11 (PennyPayDay) --Shares of micro-cap biotech TapImmune, Inc. (OTC.BB: TPIV) have seen a steady increase in volume and trading activity in recent weeks. At a volume of 1.3M (much greater than the 109,375 average volume during the regular season), shares are currently trading at $0.26, up 22%, With the World Health Organization's recent vocal announcements of growing threats that multidrug-resistant and extensively drug-resistant forms of tuberculosis are spreading at an alarming rates in Europe, investors have once again begun to pay more attention to TPIV, which holds promise as both an anti-cancer and bio-defense play. TapImmune continues working with the likes of the Mayo Clinic and Aeras Foundation on vaccine candidates in both Cancer and Infectious Diseases.
The company has been quietly building solid relationships within industry because of the relevance of the TAP technology and BioMedReports continues to expect positive developments from the firm, particularly with CEO Dr. Glynn Wilson on the verge of presenting data from the clinic on TAP levels and its affect on disease progression. There is growing evidence now from around the world showing that TAP is indeed a key component in the antigen presentation process and where it is lacking or down regulated, disease progresses and prognosis is worse.
The Seattle based company's TAP-based prophylactic vaccine -- which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times -- may significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
A next generation smallpox vaccine is currently in preclinical development and the company has been busy working with Gregory Poland, the head of the Mayo Clinic's Vaccine Research Group, who is working to unite the fields of genomics and vaccinology. That work has come about, in part, because Poland and others have never been fully pleased with the existing vaccine paradigm.
PennyPayDay Disclaimer
No comments:
Post a Comment